title: Immunostaining for rapid diagnosis of acute promyelocytic leukemia with the tetramethylrhodamine-5-isothiocyanate-conjugated anti-promyelocytic leukemia monoclonal antibody PG-M3.
abstract: BACKGROUND
  Anti-promyelocytic leukemia (PML) immunofluorescence staining is a known diagnostic tool for rapid diagnosis of acute promyelocytic leukemia (APL).
  
  
  OBJECTIVE
  We describe our methods using the recently developed, commercially available, tetramethylrhodamine-5-isothiocyanate-labeled PG-M3 anti-PML antibody for APL testing.
  
  
  METHODS
  Immunofluorescence staining with the tetramethylrhodamine-5-isothiocyanate-labeled PG-M3 antibody was used to detect PML-RARA in bone marrow aspirate and/or peripheral blood smears from 30 patients with acute leukemia. The results were compared with those of concurrent testing with our in-house polyclonal anti-PML antibody and with established tests.
  
  
  RESULTS
  All APL cases showed a positive (fine/microgranular) immunofluorescence staining pattern, whereas non-APL cases showed a negative (chunky/macrogranular) pattern. These results, which were available within 2 hours, were validated by testing with the polyclonal anti-PML antibody and with established cytogenetic and molecular testing methods.
  
  
  CONCLUSIONS
  We validated the utility of the tetramethylrhodamine-5-isothiocyanate-labeled anti-PML antibody PG-M3 for the diagnosis of APL. Our results indicate that immunofluorescence staining with this antibody is a rapid and reliable method for the diagnosis of APL.
authors.affiliation: From the Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston (Drs Alayed, Medeiros, Konoplev, and Bueso-Ramos, Mr Phan, Ms Ojiaku, Ms Patel, Ms McCord, Mr Yap, and Ms Woods); and the Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia (Dr Alayed).
authors.forename: Khaled M
authors.initials: KM
authors.lastname: Alayed
authors.forename: L Jeffrey
authors.initials: LJ
authors.lastname: Medeiros
authors.forename: Danh
authors.initials: D
authors.lastname: Phan
authors.forename: Chinemerem
authors.initials: C
authors.lastname: Ojiaku
authors.forename: Jyoti
authors.initials: J
authors.lastname: Patel
authors.forename: Jan Paul V
authors.initials: JP
authors.lastname: Yap
authors.forename: Yen
authors.initials: Y
authors.lastname: McCord
authors.forename: Janaya S
authors.initials: JS
authors.lastname: Woods
authors.forename: Sergej
authors.initials: S
authors.lastname: Konoplev
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Bueso-Ramos
authors.forename: Steven R
authors.initials: SR
authors.lastname: Reyes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal; D005260:Female; D005455:Fluorescent Antibody Technique; D005456:Fluorescent Dyes; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000276:immunology / Q000378:metabolism*; D000071156:Promyelocytic Leukemia Protein; D011446:Prospective Studies; D012235:Rhodamines; D014157:Transcription Factors / Q000276:immunology / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000276:immunology / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D005456:Fluorescent Dyes; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D012235:Rhodamines; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; C009434:tetramethylrhodamine isothiocyanate